He then built the domestic and international commercial team for Salient Surgical Technologies, culminating in a successful acquisition by Medtronic in 2011. With his leadership the business grew from $40M in revenue to over $350M. John has most recently led commercial teams at Outset Medical and Dilon Technologies.  

John is a graduate of Indiana University where he earned a degree in Public Financial Management.

The Company’s first marketed product, JUXTAPID^® (lomitapide) was approved by the US Food and Drug Administration in December 2012 for homozygous familial hypercholesterolemia.

During his tenure, JUXTAPID obtained marketing approval in 36 countries. Additionally, Aegerion acquired its second product, MYALEPT^®(metreleptin), approved in the US for generalized lipodystrophy, an ultra-rare disease.

In April 2000, Marc became the Founding CEO of ViaCell (NASDAQ:VIAC), a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc’s leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (NYSE: PKI).

While serving as CEO of ViaCell, Marc also served as a member of the board of directors of Erytech Pharma (NASDAQ:ERYP), a publicly traded biopharmaceutical company. Prior to ViaCell, Marc held various positions within Genzyme, most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing rare disease populations on a global scale.

Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (NYSE: ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts and served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.

Marc was also Founding Chairman of the board of directors and chairman of the compensation committee of Good Start Genetics, Inc., recently acquired by InVitae (NASDAQ:NVTA). He is the Founding Chairman of the board, chairman of the compensation committee and member of the audit committee of Minerva Neurosciences Inc. (NASDAQ: NERV); and a member of the Miami University Business Advisory Council and previously a member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council. Marc holds a BS from Miami University (Ohio).

At Smith & Nephew Scott led the Global Sales Excellence program and was Global Lead for the Trauma and Recon Divisions, pushing S&N to be the fastest growing company in Orthopaedics from 1999 to 2006.

In his role at Covidien, Scott was the first President of the Surgical Device business during the public roll out and was responsible for the largest revenue and cash contributor in COV’s portfolio. During his tenure the company added $1B in top line through product launches and sales force excellence programs and grew bottom line with significant gains in pricing and margin expansion across the portfolio.

Recruited to the MAKO Board for his Orthopaedic Commercial Experience, Scott helped to lead the company through its $1.7B acquisition by Stryker.

With his commercial expertise in instrumentation and portfolio strategy, Scott was recruited to the board of Invuity where he later moved into the role of Interim CEO and led a restructuring of the company, resulting in achievement of top line growth while taking $40M of cost from the business. Leading a $30M follow on financing round, Scott then led the company through its 10x acquisition by Stryker.

Returning to the Board of Conventus Orthopaedics where he had previously been Interim CEO, Scott then led a restructuring effort, helping the company with Business Development efforts and resulting in the Merger with Flower Orthopaedics and the acquisition of lower extremity fracture nailing products. Conventus is still operating as an independent company under the Deerfield Portfolio. 

In developing his consulting company MR Flora has executed Advisory work for CareSyntax inc, Corza/GTCR, CVC Capital, Metalmark Capital, Shore Capital, Integrum AB, Iridex inc., Cinven Capital, CRG. 

John was also formerly Vice-President of R&D for Solace Therapeutics, a venture funded medical device startup. Earlier, he was General Manager, North America for a subsidiary of Valeo, SA. He also has held medical device product development leadership positions at Baxter Healthcare and CR Bard.

John is also President, Founder, and Principal Consultant for Clover Medical, LLC, a medical device consulting firm. John has a BS in Biomedical Engineering and an MS in Electrical Engineering from Boston University. He holds an MBA in General Management from Northwestern University’s Kellogg School of Management.